Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPM514 in Esophageal Squamous Cell Carcinoma
NCT06690476Phase 1Recruiting
- Sponsor
- Peking University
- Start
- Oct 2024
- Primary completion
- Jul 2026
- Modality
- Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of IPM514 in Esophageal Squamous Cell Carcinoma (ESCC) (3 arms), sponsored by Peking University. Primary endpoints: Safety and tolerability up to 12 months, Maximum Tolerated Dose and Recommended Phase 2 Dose up to 12 months and 2 more. Started Oct 2024; status: recruiting.
02
Drugs
IPM514
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06690476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06690476.